Share Name Share Symbol Market Type Share ISIN Share Description
Smiths Group Plc LSE:SMIN London Ordinary Share GB00B1WY2338 ORD 37.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -55.50 -3.49% 1,535.00 1,525.50 1,526.50 1,572.00 1,524.00 1,568.00 654,067 16:35:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Industrials 2,548.0 133.0 66.9 22.9 6,079

Smiths Share Discussion Threads

Showing 1026 to 1048 of 1050 messages
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days before Xmas and part of our discussion includes SMIN which C3 holds. We also chatted about loads of other Stocks and Ideas for research. We discussed the outlook for Markets and the most likely roadmap for the next couple of months, and as usual a fair bit of educational stuff with regards to Investing. Anyway, if you use Youtube, Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 38) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, not like all the stuffy financial fodder you are probably more used to !! Season’s Greetings !! WD @wheeliedealer hTTps://
Nice update, glad I got this in the march crash. Still holding, not jumping yet.
Rerating going
Bought 3 months ago based purely on ventilator manufacturing as a hedge against Covid. Then realise their full medical and security range.Excellent British company.Up 60 % in 3 months
07:51 - Industrial and medical products supplier Smiths booked a 19% fall in first-half profit and said a spin-off of its medical division was on track for the first half of 2020. Net profit, including one-off profits and losses from discontinued operations, fell to £227m, down from £279m on-year. Pre-tax profit from continuing operations rose 19% to £142m, as revenue from continuing operations rose 7% to £2.50bn. The company's operating margin rose 40 basis points to 17.1%. Smiths declared a full-year dividend of 45.90p per share, up 3% on-year. Its medical division returned to growth in the second half with revenue up 2%, delivering flat revenue for the year overall at £874m, in line with expectations. Headline operating profit in the division, however, fell 6% on an underying basis. Smiths said that it expected to notch further overall growth in the current financial year, weighted towards the first half that would result in a more even balance in overall performance between the first and second halves. 'We continue to build sustainable growth, paving the way to outperform our markets,' chief executive Andy Reynolds said. 'Importantly, this growth was coupled with enhanced margins, we have now delivered a 300 basis points margin improvement since 2016.' 'In addition, we continued to optimise our portfolio, with two acquisitions completed in the year.'
Bidders circling - Daily Mail.
UK airports likely to purchase new scanners as per news stories.Should be beneficial for Smith's Group.
rather interesting
double cap viewable options
All seems in line, looking forward to unlocking significant value from the demerger, conglomerates rarely work for shareholders. No brainer long term investment alongside PRU and WTB where demerger value will always flow through with patience. I am a happy holder and will add on any dips.
dustrial technology company Smiths Group booked a 13% fall in first-half profit as it revealed plans to spin off its under-performing medical business into a separately listed company. Pre-tax profit for the year through January declined to £174m, even as revenue rose 2% to £1.57bn. On an underlying basis, pre-tax profit fell by a more modest 1% to £216m. The company's operating margin fell 140 basis points to 13.5%. Smiths Group declared an interim dividend of 14.1p per share, up 2.2% on-year. The company said it expected to complete the demerger process during the first half of calendar 2020, conditional on shareholder approval. 'Smiths delivered another good performance in the first half with sustainable growth driven by John Crane, Flex-Tek and Smiths Interconnect,' chief executive Andy Reynolds Smith said. 'The strong results from these divisions were partly offset by the anticipated decline in Smiths Medical and the timing of deliveries in Smiths Detection, with both on track to deliver growth in the second half.' 'Today we have announced our plans for the separation of Smiths Medical to create two stronger companies each focusing on accelerating the execution of their plans and maximising the opportunities in their respective markets. 'We reaffirm our outlook for 2019.' 'We expect to continue to deliver sustainable underlying revenue growth of at least 2%, underpinned by current trading of our four industrial technology divisions and by the increasing contribution from new product launches in Smiths Medical.'
Smiths Group, the FTSE-100 in‎dustrial conglomerate, is close to calling off talks with a rival about a £7bn merger that would have created a transatlantic healthcare giant. Sky News has learnt that Smiths is leaning towards a decision to halt negotiations with Nasdaq-listed ICU Medical about a tie-up more than two months after they got underway. A final decision has yet to be made by Smiths' chief executive, Andy Reynolds Smith, and a person close to the British company insisted on Tuesday night that any change in its position would be announced immediately to the London Stock Exchange. Banking sources said that news of the talks between Smiths and ICU, which were confirmed after Sky News revealed them in May, had prompted Baxter International, another US healthcare company, to express an interest in buying Smiths Medical outright. It was unclear whether any live talks were still taking place between Smiths and Baxter or any other potential suitors. News of the discussions was welcomed by Smiths investors in May amid hopes that the company was close to unlocking part of the value bound up in its conglomerate structure. Since then, both Smiths and ICU are said to have tabled a string of proposals about how a combination could work, with varying degrees of governance and management control being held by the two parties. ICU, which makes devices used in infusion therapy and oncology, is thought to have been keen on a formal merger of the businesses rather than a more straightforward joint venture. The Nasdaq-listed ICU has a market value of $6bn‎ (£4.6bn), while Smiths Medical was likely to have been valued at more than £2.5bn (£1.9bn) in a transaction. The US-based company has a long track record of takeovers including the $900m purchase completed last year of Pfizer's Hospira Infusion Systems arm. Smiths Medical, which also supplies advanced devices to healthcare markets around the world, accounts for just under 30% of the group's revenues, making it the company's largest unit on that basis. Its performance has been rocky in recent years, with revenue in the half-year to January down 5% to £451m. Last month, Smiths Group shares tumbled after the company said that changes to European Union rules on medical devices would hurt sales from 2020. The company said this year that it was making "significant progress on its return to growth" in the medical‎ arena but cautioned that higher research and development costs were having an impact on short-term profitability. Smiths also operates in areas such as security detection, making much of the body-scanning equipment used at airports around the world. In total, it has five main divisions‎, which also include John Crane, a provider of engineering solutions for energy and other process industries. The company's structure has long been a source of consternation for some investors and analysts, although talk of a takeover or break-up has never resulted in significant corporate activity. In recent months there has been growing talk among City investors that Smiths is likely to attract the attention of an activist investor keen on pressing more aggressively for a break-up, although its shares have generally performed strongly in recent months and are up modestly over the last year. Such activism has become increasingly common in the UK‎, with companies including FirstGroup, the transport operator, drug-maker Shire and Costa Coffee-owner Whitbread all the subject of current campaigns. Mr Reynolds Smith, who joined the company in 2015 from GKN, the engineering firm which has just been bought by Melrose Industries, is under pressure to demonstrate that its existing structure continues to deliver benefits to shareholders.
Article in The Times today - "early stage", "joint venture" etc Smiths Group in talks over healthcare ‘merger’ with US rival ICU Medical //
Getting a nice little run going.
Smiths Group was a 'hold' for the Sunday Times' Inside the City column as chief executive Andy Reynolds Smith puts his shirt on full-year results from the engineering conglomerate in the autumn. The group is divided into five divisions: Smiths Medical, Smiths Detection, Smiths Interconnect and Flex-Tek. John Crane makes mechanical seals, couplings and filtration systems; Smiths Medical specialises in catheters, needles, systems for managing airway and temperature and emergency patient transport; Detection's products are sensors and systems for airports; Interconnect's are electronic connections, including cables and wireless; while Flex-Tek provides components to heat and move fluids and gases for the aerospace, medical, industrial, construction and domestic appliance markets. The first two contribute more than a quarter of groups revenues each, detection just under a quarter and the latter two around 10% apiece. Reynolds Smith was appointed with a growth remit and has been acquisitive in since joining in September 2015. The following year the shares surged 50%, but until the start of April had nothing to show. Interim results in March knocked disappointed the market as profit fell and missed analysts' forecasts. “The time is coming when he will be judged by the measurable impact of his actions — including the purchase of Morpho — rather than presentations,”; Investec said. In order to meet the CEO's full year targets, revenues need to jump after slipping 1% in the first half at constant currency levels.
Q&A from the recent conference call are well worth a listen. Was not surprised to see the share price recover somewhat on Friday.
Rather silent in here - good upwards movement over next few weeks IMO
Another neglected thread. Positive comment this morning on US tax implications.
Industrial technology firm Smiths Group has spent most of the past year offloading different businesses but the rumour doing the rounds in the City today was it could soon change tack. On a quiet Friday, the hearsay was that the FTSE 100 company has its eye on Accelerate Diagnostics, a little-known US medical technology firm worth $1.3 billion (£1 billion) on Nasdaq. The Arizona-based company is working towards commercialising technology which helps to diagnose infectious diseases sooner. Its shares rose 5% yesterday against a falling market with trading volumes much higher than normal. Although Smiths’ name is in the frame for a potential tilt, larger US groups have a head-start on it, sources said. Frontrunners for Accelerate are said to be Thermo Fisher Scientific and Boston Scientific — both are much larger and have far more firepower than Smiths, whose operations range from energy services to specialist medical devices. It has sold several non-core business over the past year to buoy the balance sheet. After recent falls, Accelerate’s shares are now changing hands for only $23 a pop. Gossips said Accelerate and its directors, who control a large chunk of the company, would hold out for at least $35 a share. Smiths and Accelerate said they do not comment on speculation. Shares in Smiths were down 10.15p to 1553p, tracking UK stocks lower as investors digested the Barcelona terror attack and the increasingly chaotic nature of Donald Trump’s presidency. London Ev Standard HTTPS://
SMIN 1,553 is starting to look like the only way is up in near future.
Poached and on gardening leave or blackhole?
Out on todays news.
Chat Pages: 42  41  40  39  38  37  36  35  34  33  32  31  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210512 02:05:28